David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer

   David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer

PR Newswire

REDWOOD CITY, Calif., Sept. 4, 2013

REDWOOD CITY, Calif., Sept. 4, 2013 /PRNewswire/ --AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that David H. Chung has joined
the company as chief commercial officer effective September 2, 2013. Mr.
Chung brings over 20 years of hospital-focused, global medical device and
pharmaceutical sales and marketing experience, most recently as chief
commercial officer at Conceptus, Inc., which was recently acquired by Bayer.
Mr. Chung will provide strategic input to AcelRx and will be responsible for
establishing, developing and leading the Company's commercial operations.

"David has extensive sales and marketing experience in the hospital-based
products market, and a proven track record of commercial success," said
Richard King, AcelRx's president and CEO. "We are extremely excited to
welcome David to the AcelRx executive team, and we look forward to David's
leadership in establishing and building a first class commercial organization
to support, if approved, launch of Zalviso™ for management of moderate to
severe acute pain in the hospital setting."

While at Conceptus, Mr. Chung oversaw the strategic and day-to-day leadership
of a global sales and marketing organization that consisted of 144 people.
Prior to Conceptus, Mr. Chung served as president and CEO of Mitralis, an
early stage transcatheter mitral valve repair company. Prior to Mitralis, Mr.
Chung held the position of global vice president, commercial operations, Heart
Valve Therapy at Edwards Lifesciences/Baxter Healthcare, the culmination of 15
years at the company in various commercial roles of increasing
responsibility. Prior to Baxter, Mr. Chung began his career at Pfizer in a
sales capacity in both the medical device and pharmaceutical sales arenas.
Mr. Chung earned a B.S. in general engineering from the United States
Military Academy, West Point, N.Y.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. AcelRx's lead product candidate,
Zalviso™, is designed to solve the problems associated with post-operative
intravenous patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine, the
invasive IV route of delivery and the complexity of infusion pumps. AcelRx
has announced positive results from each of the three Phase 3 clinical trials
for Zalviso and AcelRx anticipates submitting a New Drug Application (NDA)
with the FDA in the third quarter of 2013. AcelRx also announced positive
top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for
the treatment of moderate-to-severe acute pain, funded through a grant from
the U.S. Army Medical Research and Materiel Command. The company has two
additional pain treatment product candidates, ARX-02 and ARX-03, which have
completed Phase 2 clinical development. For additional information about
AcelRx's clinical programs, please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not
limited to, statements related to the process and timing of anticipated future
clinical development of AcelRx Pharmaceuticals' product candidates, the
potential submission of an NDA for Zalviso and the timing thereof, therapeutic
and commercial potential of Zalviso and the anticipated timing and therapeutic
and commercial potential of other AcelRx product candidates. These
forward-looking statements are based on AcelRx's current expectations and
inherently involve significant risks and uncertainties. AcelRx's actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to: the
success, cost and timing of AcelRx's product development activities and
clinical trials; any delays or inability to obtain, regulatory approval of its
product candidates; its ability to obtain adequate clinical supplies of the
drug and device components of its product candidates; its ability to attract
funding partners or collaborators with development, regulatory and
commercialization expertise; its ability to obtain sufficient financing to
complete development and registration of its product candidates in the United
States and Europe; its ability to obtain and maintain regulatory approvals of
its product candidates; the market potential for its product candidates; the
accuracy of AcelRx's estimates regarding expenses, capital requirements and
needs for financing; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx's U.S. Securities and Exchange Commission filings and
reports, including its Quarterly Report on Form 10-Q for the three months
ended June 30, 2013, filed August 12, 2013. AcelRx undertakes no duty or
obligation to update any forward-looking statements contained in this release
as a result of new information, future events or changes in its expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO )

SOURCE AcelRx Pharmaceuticals, Inc.

Website: http://www.acelrx.com
Contact: Jim Welch, Chief Financial Officer, 650.216.3511, jwelch@acelrx.com